Clinical Trials Logo
NCT number NCT03392805
Study type Interventional
Source University of Roma La Sapienza
Contact Gabriella d'Ettorre, MD PhD
Phone +39-06-49970324
Email gabriella.dettorre@uniroma1.it
Status Recruiting
Phase N/A
Start date January 1, 2016
Completion date December 31, 2019

Clinical Trial Summary

exercise and physical activity can have an anti-inflammatory effect, while there is evidence that a sedentary lifestyle could be the basis for the development of systemic inflammation and increased cardiovascular risk. The primary objective is to assess whether regular physical activity is able to induce a decrease in systemic immune-activation in HIV positive patients.


Clinical Trial Description

Many studies document that exercise and physical activity can have an anti-inflammatory effect, while there is evidence that a sedentary lifestyle could be the basis for the development of systemic inflammation and increased cardiovascular risk. This occurs because a sedentary lifestyle leads to the accumulation of visceral fat, and this is accompanied by an increase in adipokine release and infiltration of adipose tissue by the pro-inflammatory immune cells. Furthermore, the imbalance between immune processes and metabolic processes is associated with the development of insulin resistance, atherosclerosis and neurodegeneration.

The primary objective is to assess whether regular physical activity is able to induce a decrease in systemic immune-activation in HIV positive patients.

To evaluate this hypothesis, the following parameters will be analyzed: evaluation of immune-activation levels, of metabolic parameters, of cardiac function, of immuno-virological set-up, of dietary intake and of physical performance indices in HIV-positive patients with a sedentary lifestyle; these data will be compared with the values measured in the same HIV positive population with a sedentary lifestyle after three months of regular physical activity.


Study Design


Related Conditions & MeSH terms


See also
  Status Clinical Trial Phase
Recruiting NCT03227731 - Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women Phase 2/Phase 3
Not yet recruiting NCT03311945 - Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM Phase 3
Active, not recruiting NCT03251690 - Switching TDF/FTC/EFV to TDF/FTC/RPV VS Continuing TDF/FTC/EFV in HIV Patients With Complete Virological Suppression N/A
Not yet recruiting NCT03199690 - A Clinical Study Investigating Rifampicin and Dolutegravir in Combination in Healthy Volunteers Phase 1
Active, not recruiting NCT01466582 - Comorbidity and Aging With HIV N/A
Recruiting NCT03148964 - Primary Infection Cohort N/A
Active, not recruiting NCT03312244 - Pyridostigmine as Immunomodulator in People Living With HIV Phase 2
Withdrawn NCT03074786 - Reversing the Epidemic in Africa With Choices in HIV Prevention (REACH) Phase 2
Not yet recruiting NCT03333083 - Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen Phase 3
Recruiting NCT03101592 - INTERVAL: Varying Intervals of ART to Improve Outcomes in HIV N/A
Recruiting NCT03164135 - Safety of Transplantation of CRISPR CCR5 Modified CD34+ Cells in HIV-infected Subjects With Hematological Malignances N/A
Recruiting NCT03160105 - Evaluation of a Simplified Strategy for the Long-term Management of HIV Infection (Simpl'HIV) Phase 4
Recruiting NCT03399903 - Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection Phase 1/Phase 2
Recruiting NCT03087890 - Impact of Cotrimoxazole Use in Immunocompetent HIV Patients on Carriage of Antimicrobial Resistant Bacteria Phase 4
Not yet recruiting NCT03416790 - IMPAACT 2015 - Evaluation of the HIV-1 Reservoir in the Central Nervous System of Perinatally-Infected Youth and Young Adults With Cognitive Impairment N/A
Recruiting NCT03405935 - A Study to Evaluate Switching From an E/C/F/TAF FDC Regimen or a TDF Containing Regimen to B/F/TAF FDC in HIV-1 Infected Adults Phase 3
Recruiting NCT03129113 - Adding MAraViroc &/or METformin for Hepatic Steatosis in People Living With HIV Phase 2/Phase 3
Recruiting NCT03174977 - Pharmacokinetics Distribution of Raltegravir by PET/MR Early Phase 1
Active, not recruiting NCT03110380 - Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Adults Who Are Virologically Suppressed Phase 3
Completed NCT03399136 - Fitness and Longevity in Exercise N/A